## Health Partners •••• Medicare

## PRIOR AUTHORIZATION REQUEST FORM

Bosentan - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.		
Patient Name:	Prescriber Name:	
Member Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
Line of Business:	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
☐ REQUEST FOR EXPEDITED REVIEW: By checking this the life or health of the enrollee or the enrollee's ability to	ox and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize regain maximum function.	
Drug Name:		
Strength:		
Directions / SIG:		
	tory including labs and information for this member that may support approval. se answer the following questions and sign.	
Q1. Is the prescriber a cardiologist or pu		
☐ Yes	□ No	
Q2. Is the patient between 3 and 15 years If Yes, go to 11.	's of age?	
☐ Yes	□ No	
Q3. Is the patient 15 years of age or old	er?	
☐ Yes	□ No	
Q4. Is the patient a female? If No, go to 9.		
☐ Yes	□ No	
Q5. Is the patient pregnant?		
☐ Yes	□ No	
Q6. Is the patient able to get pregnant?		
☐ Yes	□ No	
Q7. Will the patient use reliable forms o	contraception?	
☐Yes	□ No	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

## Health Partners ••• Medicare

## PRIOR AUTHORIZATION REQUEST FORM

Bosentan - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

atient Name:	Prescriber Name:
Q8. Will the patient have pregnancy tests before therapy	initiated and monthly during therapy?
Yes	□ No
Q9. Does the patient have a diagnosis of World Health O (PAH)?	rganization (WHO) Group 1 pulmonary arterial hypertension
Yes	□ No
Q10. Has the diagnosis of pulmonary arterial hypertensio catheterization (RHC)? If yes, please attach documentation	
PAH is defined as: A) A mean pulmonary arterial pressure (mPAP) greater th B) A pulmonary capillary wedge pressure/ left ventricular 15 mmHg C) A pulmonary vascular resistance (PVR) greater than 3	end-diastolic pressure (PCWP/LVEDP) less than or equal to
☐Yes	□ No
Q11. Does the patient have the diagnosis of idiopathic or by a mean pulmonary arterial pressure (mPAP) greater the	congenital pulmonary arterial hypertension (PAH), confirmed nan or equal to 20 mmHg?
Yes	□ No
Q12. Does the patient have a contraindication to bosenta	n, including use with cyclosporine A or glyburide?
Yes	□ No
Q13. Will serum transaminase (aspartate aminotransferamonitored prior to initiation of treatment and then monthly	se [AST] and alanine aminotransferase [ALT]) and bilirubin be thereafter?
Yes	□ No
Q14. Additional Information:	
Q15. Requested Duration:	
☐ 12 Months	
Prescriber Signature	Date
	2022 Medicare Prior Authorization Reque

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document